Method and formulation for treating candidiasis using morinda citrifolia

ABSTRACT

The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed  Morinda citrifolia -based naturaceutical formulations comprising one or more of a processed  Morinda citrifolia  fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract, etc., for inhibiting and preventing the overgrowth of Candida fungus and for treating Candidiasis and its associated symptoms.

RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional ApplicationNo. 60/331,504, filed Nov. 14, 2001, entitled, “Method and Formulationfor Treating Candidiasis Using Morinda Citrifolia Juice.”

BACKGROUND

[0002] 1. Field of the Invention

[0003] The present invention is directed toward methods and formulationsfor treating Candidiasis, and particularly towards various methods andnaturaceutical formulations, compositions, and substances comprisingMorinda citrifolia for inhibiting, blocking, and preventing theovergrowth of Candida albicans in mammals.

[0004] 2. Background of the Invention

[0005] There exists in the body literally billions of microorganismsthat function to assist in everyday maintenance and development. Thisnormal resident microbial population includes potential pathogens aswell as organisms that help to keep the potential pathogens in check.

[0006] Microorganisms Candida albicans, and other strains of Candida,are yeast or yeast-like fungi that are capable of growing on and withinthe human body and that normally or naturally inhabit our digestivesystem: the mouth, throat, intestines and genitourinary tract. Candidais a normal part of the bowel flora (the organisms that naturally liveinside our intestines, and are not parasitic). It has many functionsinside our digestive tract, one of them which is to recognize anddestroy harmful bacteria. Without Candida albicans in our intestines wewould be defenseless against many pathogenic bacteria. Under normalcircumstances, a healthy individual can have millions of Candidaalbicans in their system.

[0007] Our immune system is supposed to keep these organisms undercontrol, together with various strains of friendly bacteria, such asLactobacillus acidophilus, B. bifidum, Lactobacillus bulgaricus, S.thermophilus, and L. salivarius. However, if the number of friendlybacteria is decreased (e.g., as a result of antibiotics, pesticides,chlorine, etc.) in relation to the number of Candida, the immune systemis weakened and other conditions for yeast proliferation occur (e.g.,improper pH in the digestive system, or high sugar diet). Candidaalbicans will shift from yeast to a mycelial fungal form and start toinvade the body. In the yeast state Candida is a non-invasive,sugar-fermenting organism, while in the fungal state it is invasive andcan produce rhizoids, which are very long root-like structures. Rhizoidscan penetrate mucosa or intestinal walls, leaving microscopic holes andallowing toxins, undigested food particles and bacteria and yeast toenter the bloodstream.

[0008] Certain physiological environmental conditions can promote theovergrowth of the fungus in particular areas of the body. For example,the fungus may proliferate excessively in the mouth resulting in acondition known as thrush or may grow excessively in the genital arearesulting in what is commonly referred to as a genital yeast infection.

[0009] Women are particularly susceptible to genital yeast infections,the symptoms of which include vaginal itching, burning, redness, andirritation of the vaginal area. Severe vaginal yeast infections maycause swelling of the vulva and result in inflammation of the urinaryopening. Additionally, women may experience abnormal vaginal discharge.These symptoms can cause extreme discomfort, but are typically not lifethreatening. Other forms of Candidiasis (such as HepatosplenicCandidiasis, which occurs in cancer and leukemia patients andendocardial Candidiasis) are more serious arid require professionalmedical attention.

[0010] It is estimated that three out of four women will experience agenital yeast infection at some time in their lives. In some cases theyeast infection will be a recurring problem. Genital yeast infectionsalso occur in men, but with much less frequency than with women.Consumers spend more than 60 million dollars each year inover-the-counter yeast infection remedies in attempts to relieve thesymptoms of yeast infection or cure yeast infections. Present treatmentsinclude a number of over-the-counter creams and other topicalmedications that are placed directly on the infected area. Additionally,prescription oral medication and vaginal suppositories are alsoavailable to relieve and treat yeast infection.

[0011] The prior art treatments for yeast infections described above canbe unpleasant and in some circumstances are not practical. Creams andtopical lotions can be messy and uncomfortable and must be applied inprivate. In order to receive prescription medications, an infectedperson may have to endure the inconvenience of being examined by adoctor and having the prescription filled at a pharmacy. Suppositorytype treatments are considered by many to be undesirable. Anotherproblem with the over-the-counter prior art treatments described aboveis that they fail to safeguard against the potential harm from improperuse of the medication. It is reported that people experiencing thesymptoms of yeast infections such as those described above will oftenself-diagnose themselves as having a yeast infection, when in fact theydo not. Studies show that, more often than not, such self-diagnosis isincorrect. Thus, consumers buying over-the-counter medications for yeastinfections may in fact be administering medications that are unnecessaryor even harmful to them. A significant amount of money is spent on overthe counter yeast infection treatments that do not work and caninterfere with proper diagnosis of the condition.

[0012] It would be a significant advancement in the art to provide animproved method for treating Candidiasis and its symptoms. It would alsobe an advancement to reduce and inhibit the overgrowth of variousmicroorganisms within the body, such as Candida fungus and specificallyCandida albicans. Stated differently, it would be an advancement in theart to provide a natural formulation that exhibits significantantimicrobial activity within the body, or that inhibits and preventsthe overgrowth of microorganisms within the body.

SUMMARY AND OBJECTS OF THE INVENTION

[0013] In accordance with the invention as embodied and broadlydescribed herein, the present invention features a method for inducingantimicrobial and antifungal activity and inhibiting and preventing theovergrowth of Candida for the purpose of treating and preventingCandidiasis through the prophylactic administration of a naturaceuticalformulation comprising at least one of a processed Morinda citrifoliaproduct. The Processed Morinda citrifolia product may be in the form offruit juice, puree juice, fruit or puree juice concentrate, oil extract,dietary fiber, or one of an alcohol or aqueous extract.

[0014] The naturaceutical formulation may be embodied in any formsuitable for systemic internalization, namely orally, topically ortransdermally, or intravenously. Moreover, the naturaceuticalformulation may contain various amounts and concentrations of theprocessed Morinda citrifolia product, along with other variousingredients, such as a carrier medium or composition in a topical dermalnaturaceutical formulation.

[0015] Though practically inedible in it's natural form, Morindacitrifolia can be processed and used within a naturaceutical formulationto treat or alleviate the symptoms of yeast infections and other relateddiseases or infections of Candidiasis.

[0016] Several experiments are presented herein that illustrate thetreatment and preventative effects of Morinda citrifolia on theovergrowth of Candida and other related microorganisms.

[0017] The present invention further features a method for administeringthe Morinda citrifolia-based naturaceutical formulation concurrentlywith a pharmaceutical medication designed to treat and preventCandidiasis. The naturaceutical formulation functions to increase theefficacy of such medications.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] It will be readily understood that the components of the presentinvention, as generally described herein, could be arranged and designedin a wide variety of different configurations. Thus, the following moredetailed description of the embodiments of the system and method of thepresent invention is not intended to limit the scope of the invention,as claimed, but is merely representative of the presently preferredembodiments of the invention.

[0019] The present invention describes and features formulations andmethods for treating Candidiasis and its related conditions through theprophylactic administration of a naturaceutical formulation orcomposition comprising one or more processed Morinda citrifoliaproducts.

[0020] The presently preferred embodiments of the invention will be bestunderstood by separating the description into sections, the firstpertaining to a general discussion regarding Morinda citrifolia,including its origins, processing techniques, and health benefits, andthe methods employed to produce and manufacture the processed Morindacitrifolia products used as key ingredients in the naturaceuticalformulations described herein; and the second being a more detailed andspecific discussion on the Morinda citrifolia-based methods andnaturaceutical formulations or compositions used to treat and inhibitthe growth of candida albicans, and to prevent such, as well as a methodfor treating and preventing Candidiasis and its associated symptoms orconditions, such treatment methods involving the prophylacticadministration of the processed Morinda citrifolia product-basedformulations as described herein. Examples of experimental studies andthe results obtained are also provided herein.

General Discussion of Morinda citrifolia and the Methods Used to ProduceProcessed Morinda citrifolia Products

[0021] The Indian Mulberry or Noni plant, known scientifically asMorinda citrifolia L. (hereinafter “Morinda citrifolia”), is a shrub orsmall tree up to 10 m in height. The leaves are oppositely arranged withan elliptic to ovate form. The small white flowers are contained in afleshy, globose, head-like cluster. The fruits are large, fleshy, andovoid. At maturity, they are creamy-white and edible, but have anunpleasant taste and odor. The plant is native to Southeast Asia and hasspread in early times to a vast area from India to eastern Polynesia. Itgrows randomly in the wild, and it has been cultivated in plantationsand small individual growing plots. The Morinda citrifolia flowers aresmall, white, three to five lobed, tubular, fragrant, and about 1.25 cmlong. The flowers develop into compound fruits composed of many smalldrupes fused into an ovoid, ellipsoid or roundish, lumpy body, withwaxy, white, or greenish-white or yellowish, semi-translucent skin. Thefruit contains “eyes” on its surface, similar to a potato. The fruit isjuicy, bitter, dull-yellow or yellowish-white, and contains numerousred-brown, hard, oblong-triangular, winged 2-celled stones, eachcontaining four seeds.

[0022] When fully ripe, the fruit has a pronounced odor like rancidcheese. Although the fruit has been eaten by several nationalities asfood, the most common use of the Morinda citrifolia plant was as a redand yellow dye source. Recently, there has been an interest in thenutritional and health benefits of the Morinda citrifolia plant, furtherdiscussed below. Because the Morinda citrifolia fruit is for allpractical purposes inedible, the fruit must be processed in order tomake it palatable for human consumption and included in thenaturaceuticals used to treat abd prevent the growth of candida albicansand Candidiasis.

[0023] Processed Morinda citrifolia fruit juice can be prepared byseparating seeds and peels from the juice and pulp of a ripened Morindacitrifolia fruit; filtering the pulp from the juice; and packaging thejuice. Alternatively, rather than packaging the juice, the juice can beimmediately included as an ingredient in another food product, frozen orpasteurized. In some embodiments, the juice and pulp can be pureed intoa homogenous blend to be mixed with other ingredients. Other processinclude freeze drying the fruit and juice. The fruit and juice can bereconstituted during production of the final juice product. Still otherprocesses include air drying the fruit and juices, prior to beingmasticated.

[0024] The present invention utilizes the fruit juice, the puree, andthe oil extracted from the Morinda Citrifolia plant. In a currentlypreferred process of producing Morinda citrifolia fruit juice, the fruitis either hand picked or picked by mechanical equipment. The fruit canbe harvested when it is at least one inch (2-3 cm) and up to 12 inches(24-36 cm) in diameter. The fruit preferably has a color ranging from adark green through a yellow-green up to a white color, and gradations ofcolor in between. The fruit is thoroughly cleaned after harvesting andbefore any processing occurs.

[0025] The fruit is allowed to ripen or age from 0 to 14 days, with mostfruit being held from 2 to 3 days. The fruit is ripened or aged by beingplaced on equipment so it does not contact the ground. It is preferablycovered with a cloth or netting material during aging, but can be agedwithout being covered. When ready for further processing the fruit islight in color, from a light green, light yellow, white or translucentcolor. The fruit is inspected for spoilage or for excessively greencolor and hard firmness. Spoiled and hard green fruit is separated fromthe acceptable fruit.

[0026] The ripened and aged fruit is preferably placed in plastic linedcontainers for further processing and transport. The containers of agedfruit can be held from 0 to 30 days. Most fruit containers are held for7 to 14 days before processing. The containers can optionally be storedunder refrigerated conditions prior to further processing. The fruit isunpacked from the storage containers and is processed through a manualor mechanical separator. The seeds and peel are separated from the juiceand pulp.

[0027] The juice and pulp can be packaged into containers for storageand transport. Alternatively, the juice and pulp can be immediatelyprocessed into a finished juice product. The containers can be stored inrefrigerated, frozen, or room temperature conditions. The Morindacitrifolia juice and pulp are preferably blended in a homogenous blend,after which they may be mixed with other ingredients, such asflavorings, sweeteners, nutritional ingredients, botanicals, andcolorings. The finished juice product is preferably heated andpasteurized at a minimum temperature of 181° F. (83° C.) or higher up to212° F. (100° C.).

[0028] Another product manufactured is Morinda citrifolia puree andpuree juice, in either concentrate or diluted form. Puree is essentiallythe pulp a separated from the seeds and is different than the fruitjuice product described herein.

[0029] Each product is filled and sealed into a final container ofplastic, glass, or another suitable material that can withstand theprocessing temperatures. The containers are maintained at the fillingtemperature or may be cooled rapidly and then placed in a shippingcontainer. The shipping containers are preferably wrapped with amaterial and in a manner to maintain or control the temperature of theproduct in the final containers.

[0030] The juice and pulp may be further processed by separating thepulp from the juice through filtering equipment. The filtering equipmentmay include a centrifuge decanter, a screen filter with a size from 1micron up to 2000 microns, more preferably less than 500 microns, afilter press, reverse osmosis filtration., and any other standardcommercial filtration devices. The operating filter pressure preferablyranges from 0.1 psig up to about 1000 psig. The flow rate preferablyranges from 0.1 g.p.m. up to 1000 g.p.m., and more preferably between 5and 50 g.p.m. The wet pulp is washed and filtered at least once and upto 10 times to remove any juice from the pulp. The wet pulp typicallyhas a fiber content of 10 to 40 percent by weight. The wet pulp may bepasteurized at a temperature of 181° F. (83° C.) minimum and then packedin drums for further processing or made into a high fiber product.

[0031] Drying may further process the wet pulp. The methods of dryingmay include freeze-drying, drum drying, tray drying, sun drying, andspray drying. The dried Morinda citrifolia pulp may include a moisturecontent in the range from 0.1 to 15 percent by weight and morepreferably from 5 to 10 percent by weight. The dried pulp preferably hasa fiber content in the range from 0.1 to 30 percent by weight, and morepreferably from 5 to 15 percent by weight.

[0032] The high fiber product may include wet or dry Morinda citrifoliapulp, supplemental fiber ingredients, water, sweeteners, flavoringagents, coloring agents, and/or nutritional ingredients. Thesupplemental fiber ingredients may include plant based fiber products,either commercially available or developed privately. Examples of sometypical fiber products are guar gum, gum arabic, soybean fiber, oatfiber, pea fiber, fig fiber, citrus pulp sacs, hydroxymethylcellulose,cellulose, seaweed, food grade lumber or wood pulp, hemicellulose, etc.Other supplemental fiber ingredients may be derived from grains or grainproducts. The concentrations of these other fiber raw materialstypically range from 0 up to 30 percent, by weight, and more preferablyfrom 10 to 30 percent by weight.

[0033] Typical sweeteners may include, but are not limited to, naturalsugars derived from corn, sugar beet, sugar cane, potato, tapioca, orother starch-containing sources that can be chemically or enzymaticallyconverted to crystalline chunks, powders, and/or syrups. Also sweetenerscan consist of artificial or high intensity sweeteners, some of whichare aspartame, sucralose, stevia, saccharin, etc. The concentration ofsweeteners may be between from 0 to 50 percent by weight, of theformula, and more preferably between about 1 and 5 percent by weight.

[0034] Typical flavors can include, but are not limited to, artificialand/or natural flavor or ingredients that contribute to palatability.The concentration of flavors may range, for example, from 0 up to 15percent by weight, of the formula. Colors may include food gradeartificial or natural coloring agents having a concentration rangingfrom 0 up to 10 percent by weight, of the formula.

[0035] Typical nutritional ingredients may include vitamins, minerals,trace elements, herbs, botanical extracts, bioactive chemicals andcompounds at concentrations from 0 up to 10 percent by weight. Examplesof vitamins one can add to the fiber composition include, but are notlimited to, vitamins A, B1 through B12, C, D, E, Folic Acid, PantothenicAcid, Biotin, etc. Examples of minerals and trace elements one can addto the fiber composition include, but are not limited to, calcium,chromium, copper, cobalt, boron, magnesium, iron, selenium, manganese,molybdenum, potassium, iodine, zinc, phosphorus, etc. Herbs andbotanical extracts include, but are not limited to, alfalfa grass, beepollen, chlorella powder, Dong Quai powder, Ecchinacea root, GingkoBiloba extract, Horsetail herb, Indian mulberry, Shitake mushroom,spirulina seaweed, grape seed extract, etc. Typical bioactive chemicalsmay include, but are not limited to, caffeine, ephedrine, L-carnitine,creatine, lycopene, etc.

[0036] The juice and pulp can be dried using a variety of methods. Thejuice and pulp mixture can be pasteurized or enzymatically treated priorto drying. The enzymatic process begins with heating the product to atemperature between 75° F. and 135° F. It is then treated with either asingle enzyme or a combination of enzymes. These enzymes include, butare not limited to, amylase, lipase, protease, cellulase, bromelin, etc.The juice and pulp may also be dried with other ingredients, such asthose described above in connection with the high fiber product. Thetypical nutritional profile of the dried juice and pulp is 1 to 20percent moisture, 0.1 to 15 percent protein, 0.1 to 20 percent fiber,and the vitamin and mineral content.

[0037] The filtered juice and the water from washing the wet pulp arepreferably mixed together. The filtered juice may be vacuum evaporatedto a brix of 40 to 70 and a moisture of 0.1 to 80 percent, morepreferably from 25 to 75 percent. The resulting concentrated Morindacitrifolia juice may or may not be pasteurized. For example, the juicewould not be pasteurized in circumstances where the sugar content orwater activity was sufficiently low enough to prevent microbial growth.It is packaged for storage, transport and/or further processing.

[0038] The processed Morinda citrifolia product may also exist as adietary fiber produced from the fruit puree. Still further, theprocessed Morinda citrifolia product may also exist in oil form, such asan oil extract. The Morinda citrifolia oil typically includes a mixtureof several different fatty acids as triglycerides, such as palmitic,stearic, oleic, and linoleic fatty acids, and other fatty acids presentin lesser quantities. In addition, the oil preferably includes anantioxidant to inhibit spoilage of the oil. Conventional food gradeantioxidants are preferably used.

[0039] The Morinda citrifolia plant is rich in natural ingredients.Those ingredients that have been discovered include: (from the leaves):alanine, anthraquinones, arginine, ascorbic acid, aspartic acid,calcium, beta-carotene, cysteine, cystine, glycine, glutamic acid,glycosides, histidine, iron, leucine, isoleucine, methionine, niacin,phenylalanine, phosphorus, proline, resins, riboflavin, serine,beta-sitosterol, thiamine, threonine, tryptophan, tyrosine, ursolicacid, and valine; (from the flowers):acacetin-7-o-beta-d(+)-glucopyranoside,5,7-dimethyl-apigenin-4′-o-beta-d(+)-galactopyranoside, and6,8-dimethoxy-3-methylanthraquinone-1-o-beta-rhamnosyl-glucopyranoside;(from the fruit): acetic acid, asperuloside, butanoic acid, benzoicacid, benzyl alcohol, 1-butanol, caprylic acid, decanoic acid,(E)-6-dodeceno-gamma-lactone, (Z,Z,Z)-8,11,14-eicosatrienoic acid,elaidic acid, ethyl decanoate, ethyl hexanoate, ethyl octanoate, ethylpalmitate, (Z)-6-(ethylthiomethyl) benzene, eugenol, glucose, heptanoicacid, 2-heptanone, hexanal, hexanamide, hexanedioic acid, hexanoic acid(hexoic acid), 1-hexanol, 3-hydroxy-2-butanone, lauric acid, limonene,linoleic acid, 2-methylbutanoic acid, 3-methyl-2-buten-1-ol,3-methyl-3-buten-1-ol, methyl decanoate, methyl elaidate, methylhexanoate, methyl 3-methylthio-propanoate, methyl octanoate, methyloleate, methyl palmitate, 2-methylpropanoic acid, 3-methylthiopropanoicacid, myristic acid, nonanoic acid, octanoic acid (octoic acid), oleicacid, palmitic acid, potassium, scopoletin, undecanoic acid,(Z,Z)-2,5-undecadien-1-ol, and vomifol; (from the roots):anthraquinones, asperuloside (rubichloric acid), damnacanthal,glycosides, morindadiol, morindine, morindone, mucilaginous matter,nor-damnacanthal, rubiadin, rubiadin monomethyl ether, resins,soranjidiol, sterols, and trihydroxymethyl anthraquinone-monomethylether; (from the root bark): alizarin, chlororubin, glycosides (pentose,hexose), morindadiol, morindanigrine, morindine, morindone, resinousmatter, rubiadin monomethyl ether, and soranjidiol; (from the wood):anthragallol-2,3-dimethylether; (from the tissue culture): damnacanthal,lucidin, lucidin-3-primeveroside, and morindone-6beta-primeveroside;(from the plant): alizarin, alizarin-alpha-methyl ether, anthraquinones,asperuloside, hexanoic acid, morindadiol, morindone, morindogenin,octanoic acid, and ursolic acid.

[0040] Recently, as mentioned, many health benefits have been discoveredstemming from the use of products containing Morinda citrifolia. Onebenefit of Morinda citrifolia is found in its ability to isolate andproduce Xeronine, which is a relatively small alkaloid physiologicallyactive within the body. Xeronine occurs in practically all healthy cellsof plants, animals and microorganisms. Even though Morinda citrifoliahas a negligible amount of free Xeronine, it contains appreciableamounts of the precursor of Xeronine, called Proxeronine. Further,Morinda citrifolia contains the inactive form of the enzyme Proxeronasewhich releases Xeronine from Proxeronine. A paper entitled, “ThePharmacologically Active Ingredient of Noni” by R. M. Heinicke of theUniversity of Hawaii, indicates that Morinda citrifolia is “the best rawmaterial to use for the isolation of xeronine,” because of the buildingblocks of Proxeronine and Proxeronase. These building blocks aid in theisolation and production of Xeronine within the body. The function ofthe essential nutrient Xeronine is fourfold.

[0041] First, Xeronine serves to activate dormant enzymes found in thesmall intestines. These enzymes are critical to efficient digestion,calm nerves, and overall physical and emotional energy.

[0042] Second, Xeronine protects and keeps the shape and suppleness ofprotein molecules so that they may be able to pass through the cellwalls and be used to form healthy tissue. Without these nutrients goinginto the cell, the cell cannot perform its job efficiently. WithoutProxeronine to produce Xeronine our cells, and subsequently the body,suffer.

[0043] Third, Xeronine assists in enlarging the membrane pores of thecells. This enlargement allows for larger chains of peptides (aminoacids or proteins) to be admitted into the cell. If these chains are notused they become waste.

[0044] Fourth, Xeronine, which is made from Proxeronine, assists inenlarging the pores to allow better absorption of nutrients.

[0045] Each tissue has cells which contain proteins which have receptorsites for the absorption of Xeronine. Certain of these proteins are theinert forms of enzymes which require absorbed Xeronine to become active.Thus Xeronine, by converting the body's procollagenase system into aspecific protease, quickly and safely removes the dead tissue from skin.Other proteins become potential receptor sites for hormones after theyreact with Xeronine. Thus the action of Morinda citrifolia in making aperson feel well is probably caused by Xeronine converting certain brainreceptor proteins into active sites for the absorption of the endorphin,the well being hormones. Other proteins form pores through membranes inthe intestines, the blood vessels and other body organs. AbsorbingXeronine on these proteins changes the shape of the pores and thusaffects the passage of molecules through the membranes.

[0046] Because of its many benefits, Morinda citrifolia has been knownto provide a number of anecdotal effects in individuals having cancer,arthritis, headaches, indigestion, malignancies, broken bones, highblood pressure, diabetes, pain, infection, asthma, toothaches,blemishes, immune system failure, and others.

[0047] The naturaceutical formulations or compositions containing one ormore processed Morinda citrifolia products may be embodied in a formsuitable for oral use, for example, as tablets, or lozenges, aqueous oroily suspensions, dispersible powders or granules, emulsions, syrups orelixirs. Compositions intended for oral use may be prepared according toany method known in the art for the manufacture of Morinda citrifoliacompositions and such compositions may contain one or more agentsselected from the group consisting of sweetening agents, flavoringagents, coloring agents and preserving agents. Tablets contain Morindacitrifolia in admixture with non-toxic pharmaceutically acceptableexcipients which are suitable for the manufacture of tablets. Theseexcipients may be for example, inert diluents, granulating anddisintegrating agents, binding agents, and lubricating agents. Thetablets may be uncoated or they may be coated by known techniques todelay disintegration and absorption in the gastrointestinal tract andthereby provide a sustained action over a longer period. For example, atime delay material such as glyceryl monostearate or glyceryl distearatemay be employed.

[0048] Aqueous suspensions contain the Morinda citrifolia in admixturewith excipients suitable for the manufacture of aqueous suspensions.Such excipients are suspending agents, for example, sodiumcarboxymethyl-cellulose, methylcellulose, hydroxy-propylmethycellulose,sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia;dispersing or wetting agents may be a naturally-occurring phosphatide,for example lecithin, or condensation products of an alkylene oxide withfatty acids, for example polyoxyethylene stearate, or condensationproducts of ethylene oxide with long chain aliphatic alcohols, forexample heptadecaethylene-oxycetanol, or condensation products ofethylene oxide with partial esters derived from fatty acids and ahexitol such as polyoxyethylene sorbitor monooleate, or condensationproducts of ethylene oxide with partial esters derived from fatty acidsand hexitol anhydrides, for example polyethylene sorbitan monooleate.

[0049] It will be understood, however, that the specific dose level forany particular patient will depend upon a variety of factors includingthe age, body weight, general health, sex, diet, time of administration,route of administration, rate of excretion, drug combination and theseverity of the particular disease undergoing therapy.

[0050] The present invention naturaceutical formulation comprising oneor more processed Morinda citrifolia products may also be embodied in anaturaceutical composition suitable for topical dermal application oradministration, for example, as a lotion, gel, ointment, cream, oralmedication, suppository, or others as commonly known in the art. Theparticular compositions comprising processed Morinda citrifolia intendedfor topical dermal application may be prepared according to any methodknown in the art for the manufacture of such topical dermal compositionsand may comprise any known additional ingredients commonly used toproduce topical dermal products. Moreover, the processed Morindacitrifolia products may be combined with various other ingredientscommonly used to treat and prevent Candidiasis and similar relatedinfections.

Present Invention Naturaceutical Formulations and Methods of Application

[0051] The present invention features a unique naturaceuticalformulation and method of administering the same to inhibit theovergrowth of various microorganisms, such as Bacillus cereus, Bacillusmycoids, Sarcina lutea, Candida albicans, Saccharomyces cerevisiae,Fusarium oxysporum var. vasinfectum, Macrophomina phaseoli, Diplodiaoryzae, Rhizoctonia solani, Helminthosporium turcicum, Aspergilluscarneus, and others, and to induce antimicrobial activity, within thebody of a mammal. Specifically, the present invention features anaturaceutical formulation adapted to inhibit overgrowth of candidaalbicans and to treat or combat and prevent Candidiasis. The presentinvention functions to advance prior art treatments of Candidiasis byproviding a naturaceutical composition formulated with one or moreprocessed Morinda citrifolia products as derived from the IndianMulberry plant. The Morinda citrifolia product is incorporated intovarious carriers suitable for in vivo treatment of a patient. Forinstance, the naturaceutical formulation may be ingested orally via anoral composition, applied topically via a topical dermal composition,introduced through an intravenous injection or feeding, or otherwiseinternalized as is appropriate and directed.

[0052] Overgrowth of microorganisms, such as candida albicans, lead toseveral known diseases or infections, collectively known as Candidiasis.As stated, microorganisms Candida albicans, and other strains ofCandida, are yeast or yeast-like fungi that are capable of growing onand within the human body and that normally or naturally inhabit ourdigestive system: the mouth, throat, intestines and genitourinary tract.Candida is a normal part of the bowel flora (the organisms thatnaturally live inside our intestines, and are not parasitic). It hasmany functions inside our digestive tract, one of them which is torecognize and destroy harmful bacteria. Without Candida albicans in ourintestines we would be defenseless against many pathogenic bacteria.Under normal circumstances, a healthy individual can have millions ofCandida albicans in their system.

[0053] Our immune system is supposed to keep these organisms undercontrol, together with various strains of friendly bacteria, such asLactobacillus acidophilus, B. bifidum, Lactobacillus bulgaricus, S.thermophilus, and L. salivarius. However, if the number of friendlybacteria is decreased (e.g., as a result of antibiotics, pesticides,chlorine, etc.) in relation to the number of Candida, the immune systemis weakened and other conditions for yeast proliferation occur (e.g.,improper pH in the digestive system, or high sugar diet). Candidaalbicans will shift from yeast to a mycelial fungal form and start toinvade the body. In the yeast state Candida albicans are a non-invasive,sugar-fermenting organism, while in the fungal state they are invasiveand can produce rhizoids, which are very long root-like structures.Rhizoids can penetrate mucosa or intestinal walls, leaving microscopicholes and allowing toxins, undigested food particles and bacteria andyeast to enter the bloodstream.

[0054] The naturaceutical composition of the present invention comprisesone or more processed Morinda citrifolia products present in an amountby weight between about 0.01 and 100 percent by weight, and preferablybetween 0.01 and 95 percent by weight. Several embodiments offormulations are provided below. However, these are only intended to beexemplary as one ordinarily skilled in the art will recognize otherformulations or compositions comprising one or more processed Morindacitrifolia products.

[0055] The processed Morinda citrifolia product present as an ingredientin a given or identified amount in the naturaceutical formulation isintended to function as the active ingredient or contain one or moreactive ingredients, such as Quercetin and Rutin, and others, foreffectuating the inhibition and prevention of the overgrowth of candidaalbicans, in relation to the several “friendly” bacteria, within amammal often resulting in Candidiasis, as well as for treating orrelieving pre-existing infections of Candidiasis, by inhibiting orpreventing further growth of candida albicans and inducing antimicrobialactivity within the body.

[0056] Active ingredients may be extracted out using various alcohol oralcohol-based solutions, such as methanol, ethanol, and ethyl acetate,and other alcohol-based derivatives using any known process in the art.In an exemplary embodiment, the active ingredients of Quercetin andRutin are present in amounts by weight ranging from 0.01-10 percent ofthe total formulation or composition. However, these amounts may beconcentrated into a more potent concentration, in which they are presentin amounts ranging from 10 to 100 percent of the total composition.

[0057] The processed Morinda citrifolia product may be formulated withvarious other additional ingredients to produce several differentintended purpose or use compositions and types of compositions, such asan oral naturaceutical composition, a topical dermal naturaceuticalcomposition, a systemically administered naturaceutical composition, orothers. The additional ingredients to be utilized in any of theabove-mentioned naturaceutical compositions are any that are safe forintroduction into the body of a mammal, and particularly a human, andmay exist in various forms, such as liquids, tablets, lozenges, aqueousor oily solutions, dispersible powders or granules, emulsions, syrups,elixirs, lotions, creams, gels, suppositories, ointments, etc.

[0058] In one exemplary embodiment, the present invention features amethod of administering a naturaceutical composition to a mammal for thetreatment of Candidiasis and its related conditions. The methodcomprises the steps of (a) formulating a naturaceutical compositioncomprising in part a processed Morinda citrifolia product present in anamount between about 0.01 and 100 percent by weight, and preferably 0.1to 95 percent by weight, wherein the composition also comprises acarrier, such as water or purified water, and other natural orartificial ingredients; (b) administering the naturaceutical compositioninto the body such that the Morinda citrifolia is sufficientlyinternalized and concentrated within the infected area, thus capable ofinducing antimicrobial activity therein, and to inhibit and preventfurther growth of candida albicans; (c) repeating the above steps asoften as necessary to provide an effective amount of Morinda citrifoliato the area or region infected with Candidiasis.

[0059] In one exemplary embodiment, the step of administering thenaturaceutical composition into the body comprises ingesting thecomposition orally through one of several means. Specifically, thenaturaceutical composition may be formulated as a liquid, gel, solid, orsome other type that would allow the composition to be quickly digestedand concentrated within the infected area. It is important to note thatthe step of administering the naturaceutical composition should becarried out in an effective manner so that the greatest concentration ofnaturaceutical composition is allowed to be internalized. For thenaturaceutical composition to take effect, it must be sufficientlyinternalized into the body where it may then begin to act upon theovergrowth of candida albicans within the body. Moreover, since thenaturaceutical composition will most likely be consumed orally, it maycontain one or more agents selected from the group consisting ofsweetening agents, flavoring agents, coloring agents, preserving agents,and other medicinal agents as directed.

[0060] In another exemplary embodiment, the step of administering thenaturaceutical composition into the body comprises applying a topicaldermal composition, comprising processed Morinda citrifolia as at leastone existing ingredient in the composition, to the area affected orinfected with Candidiasis. The ingredients to be utilized in a topicaldermal composition are also any that are safe for internalizing into thebody of a mammal and may exist in various forms, each comprising one ormore carrier agents. The topical dermal naturaceutical composition isapplied directly to the infected area as often as needed until growth,or overgrowth, is abated.

[0061] In still another exemplary embodiment, the step of administeringthe naturaceutical composition into the body comprises systemicallyintroducing the processed Morinda citrifolia product-basednaturaceutical composition into the body via any known means in the art,such as intravenously. The ingredients for the systemically administeredformulation may also comprise any commonly known in the art.

[0062] In still another exemplary embodiment, the step of administeringthe naturaceutical composition may include injecting the compositioninto the body using an intravenous pump. This technique is advantageousas it would allow the composition to be localized in the area where itwould have the most effect, or the area that would provide for thegreatest concentration of the naturaceutical composition.

[0063] The treatment of Candidiasis by inhibiting the overgrowth ofcandida albicans, or inducing antimicrobial activity within the body,results from the affect of these processed Morinda citrifolia products,and/or the active ingredients found therein, namely Quercetin, Rutin,Xeronine, and the building blocks to Xeronine—Proxeronase andProxeronine, on the life of these organisms and their ability tosurvive. Specifically, the processed Morinda citrifolia products,whether they be in the form of fruit juice, puree juice, dietary fiber,oil, etc., function to inhibit and prevent growth by providing aningredient or substance that is lethal, or at least significantlyinhibitory, to Candida, thus restoring a more natural balance betweencandida albicans (fungus) and friendly bacteria.

[0064] In another exemplary embodiment, the naturaceutical compositionis internalized by orally ingesting between 1 teaspoon and 2 oz., andpreferably 2 oz., every two hours each day, or at least twice a dayuntil the growth or overgrowth is abated. This process should bemaintained even after the growth is abated to prevent further overgrowthor latent overgrowth. Also, the naturaceutical composition should betaken on an empty stomach, which means a period of time at least twohours prior to consumption of any food or drink. Following this, thenaturaceutical composition actively impairs growth of the Candida andeven functions to kill many of these organisms, thereby combating theeffects of Candidiasis. Of course, one ordinarily skilled in the artwill recognize that the amount of composition and frequency of use mayvary from individual to individual.

[0065] The following tables illustrate or represent some of thepreferred formulations or compositions contemplated by the presentinvention. As stated, these are only intended as exemplary embodimentsand are not to be construed as limiting in any way. Ingredients Percentby Weight Formulation One Morinda citrifolia puree juice or fruit juice100% Formulation Two Morinda citrifolia fruit juice  10-99.99% water0.1-90% Formulation Three Morinda citrifolia fruit juice  10-99.99%non-Morinda citrifolia-based fruit juices 0.1-90% Formulation FourMorinda citrifolia fruit juice  50-90% water 0.1-50% non-Morindacitrifolia-based fruit juices 0.1-30% Formulation Five Morindacitrifolia puree juice  10-99.9% water 0.1-90% Formulation Six Morindacitrifolia puree juice  10-99.9% non-Morinda citrifolia-based fruitjuices 0.1-90% Formulation Seven Morinda citrifolia puree juice  50-90%water 0.1-50% non-Morinda citrifolia-based fruit juices 0.1-30%Formulation Eight Morinda citrifolia dietary fiber 0.1-30% water  1-99.9% non-Morinda citrifolia-based fruit juices   1-99.9%Formulation Nine Morinda citrifolia dietary fiber 0.1-30% water  1-99.9% Morinda citrifolia fruit juice or puree juice   1-99.9%Formulation Ten Morinda citrifolia oil 0.1-30% carrier medium  70-99.9%other ingredients   1-95% Formulation Eleven Morinda citrifolia fruit orpuree juice/  10-80% concentrate, oil, or dietary fiber carrier medium 20-90% Formulation Twelve Morinda citrifolia fruit or puree juice/  5-80% concentrate, oil, or dietary fiber carrier medium  20-95%Formulation Thirteen Morinda citrifolia oil or oil extract 0.1-20%carrier medium  20-90% Formulation Fourteen Morinda citrifolia pureejuice or fruit Juice 0.1-80% Morinda citrifolia oil 0.1-20% carriermedium  20-90% Formulation Fifteen Morinda citrifolia puree juiceconcentrate 100% or fruit juice concentrate Formulation Sixteen Morindacitrifolia fruit juice concentrate  85-99.99% or puree juice concentratewater 0.1-15% Formulation Seventeen Morinda citrifolia fruit juice 10-80% topical carrier composition  20-90% Formulation Eighteen Morindacitrifolia oil 0.1-80% topical carrier composition  20-99.9% FormulationNineteen Morinda citrifolia oil 0.1-20% Morinda citrifolia fruit juice0.1-80% topical carrier composition  20-90% Formulation Twenty Morindacitrifolia oil 0.1-20% Morinda citrifolia fruit juice 0.1-80% isopropylmyristate  10-20% purified water  20-30% glycerin   1-20% octyl cocoate  1-20% hydrogenated coco-glycerides   1-20% Stearyl alcohol   1-5%cetyl alcohol   1-5% butylene glycol   1-5% caprylic/capric triglyceride  1-5% glyceryl stearate citrate   1-5% shea butter   1-5% tocopherylacetate (Vitamin E)   1-5% biosaccharide gum   1-5% macadamia nut oil  1-5% ubiquinone (coenzyme Q10)   1-5% retinyl palmitate (Vitamin A)  1-5% sodium ascorbyl phosphate (Vitamin C)   1-5% tridecyl ttearate  1-5% tridecyl trimellitate   1-5% dipentaerylthirtyl hexacaprylatel  1-5% hexacaprate lanolin alcohol   1-5% carbomer   1-5% sodiumhydroxide   1-5% trisodium EDTA   1-5% phenoxyethanol   1-5%methylparaben   1-5% ehylparaben   1-5% propylparaben   1-5%butylparaben   1-5% dMDM Hydantoin   1-5%

[0066] In another exemplary embodiment, a person suffering fromCandidiasis as described above takes, or is administered, orally atleast one (1) ounce of the naturaceutical composition identified inFormulation One in the morning on an empty stomach, and at least one (1)ounce at night on an empty stomach, just prior to retiring to bed. Thisprocedure is carried out using this dosage until the growth is abated.The procedure may be continued however, to effectuate prevention offuture infections of Candidiasis and to prevent the overgrowth ofcandida albicans. In one example, which is not meant to be limiting inany way, the beneficial Morinda Citrifolia fruit juice product isprocessed into Tahitian Noni® juice manufactured by Morinda,Incorporated of Orem, Utah. A similar procedure may be carried out usingthe naturaceutical compositions identified in Formulations Two throughFormulation Nine.

[0067] As stated above, another exemplary embodiment of the presentinvention features a method for introducing a topical dermalnaturaceutical composition or formulation to a region of the bodyinfected by Candidiasis. This method essentially comprises theapplication of a naturaceutical composition, embodied in a topicaldermal composition, to the skin or mucosa of the patient, wherein thenaturaceutical is absorbed or internalized into the body through thepores or membrane. Several embodiments of the topical dermalnaturaceutical comprising various different ingredients are contemplatedfor use herein, with each embodiment comprising one or more forms of aprocessed Morinda citrifolia product as the active ingredient as taughtand explained herein, along with one or more carrier agents or mediumsand any other ingredients commonly known in the art that are appropriatefor a topical dermal composition.

[0068] In one exemplary embodiment, the topical dermal naturaceuticalcomprises the ingredients of: a processed Morinda citrifolia productpresent in an amount by weight between about 10-80 percent; and acarrier medium or composition present in an amount by weight betweenabout 20-90 percent.

[0069] In this embodiment, the processed Morinda citrifolia product maycomprise one or more of processed Morinda citrifolia fruit juice (indilute or concentrate form), processed Morinda citrifolia puree juice(in dilute or concentrate form), processed Morinda citrifolia dietaryfiber, and/or processed Morinda citrifolia oil or oil extract. Moreover,this composition may comprise extracted Morinda citrifolia products,such as Morinda citrifolia ethyl extracts, Morinda citrifolia ethanolextracts, Morinda citrifolia methanol extracts, etc.

[0070] In another exemplary embodiment, the topical dermalnaturaceutical comprises the ingredients of: processed Morindacitrifolia fruit juice or puree juice (in dilute or concentrate form)present in an amount by weight between about 0.1-80 percent; processedMorinda citrifolia oil present in an amount by weight between about0.1-20 percent; and a carrier medium or composition present in an amountby weight between about 20-90 percent. The topical dermal compositionmay also be formulated with a Morinda citrifolia dietary fiber productin similar concentrations.

[0071] Formulations Ten through Fourteen and Formulations Eighteenthrough Twenty, each identified above, are examples of some of theingredients and their concentrations that may be incorporated into thetopical dermal naturaceutical.

[0072] The carrier medium or composition in the topical dermalnaturaceutical may comprise any ingredient capable of being safelyintroduced into the body of a mammal, and that is also capable ofproviding the carrying medium for the processed Morinda citrifoliaproduct. Specific carrier mediums and compositions are well known in theart and not described in detail herein. however, Formulation Twentyidentified above illustrates one exemplary embodiment of some of thetypes of ingredients that may be incorporated into the naturaceutical.Overall, the purpose of the carrier medium is as stated, to provide ameans to embody the processed Morinda citrifolia product within thetopical dermal naturaceutical for the purpose of providing the abilityto introduce the naturaceutical into the body, and particularly, into anarea or region infected with Candidiasis.

[0073] The present invention further features taking a prescribed orover the counter pharmaceutical medication or drug, formulated for thetreatment and prevention of Candidiasis, concurrently with one of theMorinda citrifolia-based naturaceutical formulations described herein.Taking or administering the Morinda citrifolia-naturaceuticalformulation concurrently with a Candidiasis medication functions toenhance the relief potential for the patient by increasing or enhancingthe efficacy of the Candidiasis medication, as well as providing thesame benefits and advantages to the patient that are obtained directlyfrom the Morinda citrifolia-naturaceutical formulation. Pharmaceuticalsused to treat and prevent Candidiasis are well known in the art and canbe grouped into two different categories—symptomatic relief andpreventive therapy. Symptomatic relief medications are used to relievesymptoms associated with existing Candidiasis, while preventivemedications are used to reduce some of the factors that contribute tothe onset of a Candidiasis infection, or rather prevent the overgrowthof Candida.

[0074] The processed Morinda citrifolia products comprise the activeingredients Quercetin and Rutin. These active ingredients are iseffective against Candida albicans because of their ability to

[0075] The following examples set forth and present the effects ofMorinda citrifolia on healthy and degenerating cartilage, as well as thepreventative and treatment effects of Morinda citrifolia againstCandidiasis. These examples are not intended to be limiting in any way,but are merely illustrative of the benefits and advantageous, as well asthe remedial effects, of Morinda citrifolia on Candidiasis.

EXAMPLE ONE

[0076] In this example, a female patient has a vaginal yeast infectioncaused by the Candida albicans fungus. The individual suffering from theinfection has itching, burning, redness, and irritation in the vaginalarea. The individual desires to treat the condition with anonprescription, over-the-counter preparation. To treat the infection,the individual consumes a prescribed amount of a naturaceutical foodproduct composition containing processed Morinda citrifolia fruit orpuree juice. The person intermittently consumes the food productcontaining the processed Morinda citrifolia juice until the symptoms ofthe infection are relieved and/or the infection is reduced oreliminated. Alternatively, the person applies a topical dermalnaturaceutical comprising a processed Morinda citrifolia product to theinfected area at least twice a day until growth is abated and the yeastinfection is eliminated.

EXAMPLE TWO

[0077] In this example, a person is suffering from a disorder thatincreases the likelihood that the person will contract Candidiasis. Forexample, the person may have a thyroid disorder, an endocrine disorder,or be suffering from diabetes. The person consumes a naturaceutical foodproduct composition containing processed Morinda citrifolia fruit orpuree juice in order to reduce the likelihood that the person willcontract Candidiasis. In the event the person does contract Candidiasis,the consumption of the naturaceutical food product containing Morindacitrifolia juice helps to contain the infection and limit the abilityfor the infection to spread to other areas or regions.

EXAMPLE THREE

[0078] In this example, an individual is taking medications or receivingmedical treatments for an ailment other than Candidiasis. Receiving thetreatment or taking the medication increases the likelihood that theperson could contract Candidiasis. For example, the person may be takinghormonal treatments, corticosteroids, or high estrogen contraceptives.The person may be undergoing cancer or HIV therapy, or may be usingantibiotics. Additionally, the person may be concerned that takingmedications to limit or prevent yeast infection could adversely react orreduce the effectiveness of the medication the person is already taking.The person consumes a naturaceutical food product containing processedMorinda citrifolia puree juice during the period of time that themedication is being taken in order to prevent a yeast infection andoffset the increased likelihood of infection. The individual may begintaking the food product containing processed Morinda citrifolia pureejuice for a period of time prior to taking the medication in order tofurther decrease the chance of yeast infection.

EXAMPLE FOUR

[0079] In this example, a woman is pregnant rendering her moresusceptible to yeast infection. The pregnant woman is unable to takemedications to treat a yeast infection because there is the potentialfor the yeast infection medication to pass through the placenta to theembryo or fetus. In order to reduce the likelihood of a yeast infectionor to treat an existing yeast infection, the pregnant woman consumes anaturaceutical composition comprising processed Morinda citrifolia pureeor fruit juice. Pharmaceutically beneficial active ingredients in theMorinda citrifolia juice prevent or substantially reduce the woman'schance of contracting yeast infection and help to combat any existingyeast infections.

EXAMPLE FIVE

[0080] In this example, a person is suffering a condition havingassociated symptoms similar to those experienced by a person sufferingfrom Candidiasis. The person suffering from the condition is uncertainas to whether or not he or she is suffering from Candidiasis. Ratherthan attempting to self-prescribe Candidiasis medication such asover-the-counter ointments or creams, the person consumes anaturaceutical food product comprising processed Morinda citrifoliapuree or fruit juice in order to alleviate the symptoms from which theperson suffers.

EXAMPLE SIX

[0081] In an actual example as reported by Dr. Scott Gerson, preliminaryevaluations of the anti-fungal activity of extracts of Morindacitrifolia were found to be positive. In his study an mean inhibitoryconcentration (MIC) protocol was developed and then used to testethanol, methanol, ethyl acetate, and aqueous extracts of Morindacitrifolia dried and then diluted to a final concentration of 2 mg/mlfor anti-microbial activity against A. niger (ATCC 6275), C. albicans(ATCC 10231), E. coli (ATCC 25922), S. aureus (ATCC 25923), and T.mentagrophytes (ATCC 9533). These extracts each contained the isolatedand extracted active ingredients of Quercetin, Rutin, and others asderived or obtained from the Morinda citrifolia. Liquid extracts wereobtained and tested in micro titer wells in duplicate. Quantities of theextracts, ranging from 6 micro liters to 200 micro liters, were placedin the wells and dried. A McFarland 0.5 solution of each organism wasprepared, and a {fraction (1/100)} suspension into the appropriate mediawas made. This organism suspension was added to each well, and incubatedfor an appropriate amount of time at the appropriate temperature. Plateswere then examined for growth, and MIC's were determined. All duplicateresults agreed within one dilution.

[0082] The ethyl acetate extracts had the least amount of anti-microbialactivity, only showing activity when tested against T. mentagrophytesand S. aureus. The ethanol extracts showed anti-microbial activityagainst all of the organisms tested. This activity ranged from off-scaleon the low end when tested against T. mentagrophytes, to high on-scaleresults for A. niger. Methanol extracts also showed significant activityagainst all of the organisms tested, and ranged from off-scale on thelow end when tested against T. mentagrophytes, to high on-scale resultsfor A. niger. These results indicate that extracts of Morinda citrifoliacontain anti-microbial activity most significantly against variousstrains of fungi.

EXAMPLE SEVEN

[0083] The following example details another actual study conducted andthe results achieved. The purpose of the study was to determine meaninhibitory concentration (MIC) and mean lethal concentration (MLC) ofselected Morinda citrifolia extracts as processed and produced accordingto the disclosure herein against three common pathogenic fungi and twocommon bacteria, and particularly to determine the effectiveness ofusing Morinda citrifolia to treat Candidiasis.

[0084] The fungus and bacteria organisms or species used in the testwere Candida albicans (ATCC #10231), E. coli (0157H7 ATCC #43888), S.aureus (ATCC #6538), B. subtilis (ATCC #19659), S. choleraesuis serotypeenteritidis (ATCC #13706), and L. monocytogenes (ATCC #19111).

[0085] The procedure used was a standard assay for antimicrobials, whichincorporate the procedures, intent and content of the American Societyfor Microbiology recommended methodology. The antimicrobial agents wereTahitian Noni® Puree Juice (TNPJ) in different concentration(s).

[0086] The method outlined below is a summary of the methods used in theMinimum Inhibitory Concentration (MIC) and Minimum Lethal Concentration(MLC) procedures. First, the organisms were obtained from ATCC. Second,upon arrival, the organisms were transferred from stock to Casein DigestBroth (SCDB). Third, bacterial cultures were incubated at 35-39 degreesCelsius for 18-24 hours while the yeast was cultured at 20-25 degreesCelsius for 2-5 days.

[0087] MIC Test Procedure

[0088] The following outlines the test procedure for the mean inhibitoryconcentration:

[0089] 1. The TNPJ concentrate, in triplicate, was diluted serially 1:2in sterile water out to 1:32. The dilutions were added to an equalvolume if 2×SCBD to provide an additional 1:2 dilution making the finaldilutions tested in the range of 1:2 to 1:64 for all organisms except B.subtilis. B. subtilis was tested at final dilutions ranging from 1:2 to1:8.

[0090] 2. Three negative control tubes were prepared by mixing thehighest dilution tested of the TNPJ with equal volumes of 2×SCBD and NOtested organisms were added. Also, three tubes were used as positivecontrol tubes for EACH organisms were prepared by mixing sterile waterwith equal volumes of 2×SCBD.

[0091] 3. Concomitantly, 0.05 mL of suspension was added tocorresponding test sample dilution and positive control tubes for eachtest organism. Bacterial and fungal species test tubes were incubated aspreviously described.

[0092] 4. An aliquot from each tube was streaked onto appropriate agarto confirm the presence or growth after incubation. Bacterial aliquotwere plated on SCBD and yeast on SDEX and incubated as previouslydescribed.

[0093] 5. After confirmation of growth, the growth was scored as eithernegative (0) or positive (+) for each tube.

[0094] MLC Test Procedure

[0095] The following outlines the test procedure for the mean lethalconcentration. This procedure will test only the tubes either suspectedor confirmed of NOT having growth after MIC testing were tested for MLC.

[0096] 1. Serial dilutions ({fraction (1/10)}) were made to neutralizebroth up to a dilution of {fraction (1/1000)}. An aliquot from eachdilution was plated onto neutralizer agar (NUAG). As a negative control,2×SCBD was plated onto NUAG and incubated in temperature and time/day aspreciously described for bacterial and fungi.

[0097] 2. The neutralization was verified as follows. The lowestdilution of TNPJ tested for MLC was tested for neutralization recoveryof the test organisms in 2×SCBD. In triplicate, 0.5 mL aliquots of thediluted test product were plated on NUAG. The plates were spiked with10-100 CFU of the tested organisms. For comparison, three plates of NUAGwithout the test product were also spiked with the same 10-100 CFU ofthe test organism as a positive control for both neutralization and MLC.

[0098] Results Obtained for MIC Test TABLE 1 MIC results for E. coliDilution Growth (+/0) 1:2  0 0 0 1:4  + + + 1:8  + + + 1:16 + + +1:32 + + + 1:64 + + + Positive + + + Negative 0 0 0 Media 0 0 0

[0099] TABLE 2 MIC results for S. aureus Dilution Growth (+/0) 1:2 0 0 01:4 + + + 1:8 + + +  1:16 + + +  1:32 + + +  1:64 + + + Positive + + +Negative 0 0 0 Media 0 0 0

[0100] TABLE 3 MIC results for B. subtilis Dilution Growth (+/0) 1:2 0 00 1:4 + + + 1:8 + + + Positive + + + Negative 0 0 0 Media 0 0 0

[0101] TABLE 4 MIC results for Salmonella choleraesuis serotypeenteritidis Dilution Growth +/0 1:2 0 0 0 1:4 + + + 1:8 + + + 1:16 + + +  1:32 + + +  1:64 + + + Positive + + + Negative 0 0 0 Media0 0 0

[0102] TABLE 5 MIC results for Listeria monocytogenes Dilution Growth(+/0) 1:2 0 0 0 1:4 + + + 1:8 + + +  1:16 + + +  1:32 + + +  1:64 + + +Positive + + + Negative 0 0 0 Media 0 0 0

[0103] TABLE 6 MIC results for Candida albicans Dilution Growth (+/0)1:2 0 0 0 1:4 + + + 1:8 + + +  1:16 + + +  1:32 + + +  1:64 + + +Positive + + + Negative 0 0 0 Media 0 0 0

[0104] Results Obtained for MLC Test TABLE 7 E. coli Tube ReplicateDilution (+/0)  10⁻¹  10⁻²  10⁻³ 1:2 #1 0 0 0 1:2 #2 0 0 0 1:2 #3 0 0 0

[0105] TABLE 8 S. aureus Tube Replicate Dilution (+/0)  10⁻¹  10⁻²  10⁻³1:2 #1 + 0 0 1:2 #2 + 0 0 1:2 #3 0 0 0

[0106] TABLE 9 B. subtilis Tube Replicate Dilution (+/0)  10⁻¹  10⁻² 10⁻³ 1:2 #1 + + 0 1:2 #2 + + 0 1:2 #3 + 0 0 1:4 #1 + 0 0 1:4 #2 + 0 01:4 #3 + 0 0 1:8 #1 + + + 1:8 #2 + + + 1:8 #3 + + +

[0107] TABLE #10 Salmonella choleraesuis serotype enteritidis Dilution(+/0) Tube Replicate 10⁻¹ 10⁻² 10⁻³ 1:2 #1  0 0 0 1:21 #2 0 0 0 1:2 #3 0 0 0

[0108] TABLE #11 Listeria monocytogenes Dilution (+/0) Tube Replicate10⁻¹ 10⁻² 10⁻³ 1:2 #1 0 0 0 1:2 #2 0 0 0 1:2 #3 + 0 0

[0109] TABLE #12 Candida albicans Dilution (+/0) Tube Replicate 10⁻¹10⁻² 10⁻³ 1:2 #1 0 0 0 1:2 #2 0 0 0 1:2 #3 0 0 0

[0110] TABLE #13 Neutralization Neutralization Positive Count CountPercent Organism 1 2 3 Ave 1 2 3 Ave Recovery E. coli 15 14 16 15 23 1718 19 127% S. aureus 56 54 61 57 82 60 71 71 125% B. subtilis 86 91 8888 70 62 61 64  73% S. choleraesuis 34 11 26 24 35 28 17 27 113% L.monocytogenes 79 72 81 77 73 69 74 72  94% Candida albicans 54 53 49 5245 52 72 56 108%

[0111] Results Summary

[0112] The MIC test results revealed that B. subtilis was the onlyorganism that survived all dilutions of the test product while theothers were NOT recoverable as confirmed by the streak plates' resultsfor the 1:2 dilution, as shown in Tables 1-6. In other words, the testproduct was lethal and inhibitory at the indicated dilution.

[0113] The result of the MLC test confirmed that the product was alsolethal to E. coli, S. choleraesuis serotype enteritidis and Candidaalbicans.

[0114] However, the test product was inhibitory to the S. aureus and L.monocytogenes while it has no effect on the growth of B. subtilis. Thatis to say, that none of the dilutions indicated have an effect on thegrowth of B. subtilis.

EXAMPLE EIGHT

[0115] Similar to the other above-identified examples, the purpose ofthis experiment was to determine mean inhibitory concentration (MIC) ofselected processed Morinda citrifolia fruit juice extracts against threecommon pathogenic fungi and two common bacteria, namely, Aspergillusniger (ATCC 6275), Candida albicans (ATCC 10231), Trichophytonmentagrophytes (ATCC 9533), Staphlococcus aureus (ATCC 29213), andEscherichia coli (ATCC 9533).

[0116] The processed Morinda citrifolia extracts comprised ethanol,methanol, ethyl acetate, and aqueous extracts. Each of these wasprepared using appropriate solvents.

[0117] Sterile Media Preparations (1 Liter)

[0118] 1. Fungi: Sabouraud Dextrose Broth

[0119] 2. Bacteria: Mueller Hinton Broth

[0120] 3. Autoclave at 121° C. for 20 minutes

[0121] Organism Suspension Preparations

[0122] 1. Plated each organism on appropriate media.

[0123] 2. Incubated and confirmed identity.

[0124] 3. Prepared 0.5 McFarland suspension of each organism.

[0125] 4. Added 0.1 ml of the organism to 9.9 ml of the appropriatemedia (SDB or MHB).

[0126] Preparation of Morinda citrifolia Extracts

[0127] Using appropriate media, the extracts were dried and then dilutedto a final concentration of 2 mg/ml. These 2 mg/ml final volumes wereused as Morinda citrifolia stock solutions. The extracts were stored in−20° C. freezers until ready for fungal plating.

[0128] Thirteen test tubes were labeled as follows: {fraction (1/1)},{fraction (1/32)}, {fraction (1/512)}, ½, {fraction (1/64)}, {fraction(1/1024)}, ¼, {fraction (1/128)}, GC (Growth Control), ⅛, {fraction(1/256)}, NC (Non-inoculated Control), and {fraction (1/16)}. Thefollowing procedures were then performed:

[0129] 1. 100 μl of Morinda citrifolia stock solution was added to Tube{fraction (1/1)} and 100 μl to Tube ½.

[0130] 2. 100 μl of sterile media was added to Tubes: ½, ¼, ⅛, {fraction(1/16)}, {fraction (1/32)}, {fraction (1/62)}, {fraction (1/128)},{fraction (1/256)}, {fraction (1/512)}, {fraction (1/1024)}, GC, and NC.

[0131] 3. Tube ½ was mixed well and 100 l removed and added to Tube ¼.

[0132] 4. This two-fold dilution procedure was continued for Tubes ⅛,{fraction (1/16)}, {fraction (1/32)}, {fraction (1/64)}, {fraction(1/128)}, {fraction (1/256)}, {fraction (1/512)}, and {fraction(1/1024)}.

[0133] 5. Doscarded 100 l from Tube {fraction (1/1024)}. No diluted TNJsolution was added to Tubes GC or NC. These were the control tubes.

[0134] 6. At This point all tubes contained 100 l.

[0135] 7. Because it was known that 2 mg/ml (i.e. 2000 g/ml) of theextract stock solution was initially started with, the serial two-folddilution resulted in the following concentrations of TNJ extract: TABLE#13 Concentration of TNJ Extract in Each Tube Tube Number DilutionConcentration of Extract 1 {fraction (1/1)} 2000 ug/ml 2 ½ 1000 ug/ml 3¼ 500 ug/ml 4 ⅛ 250 ug/ml 5  {fraction (1/16)} 125 ug/ml 6  {fraction(1/32)} 62.50 ug/ml 7  {fraction (1/64)} 31.25 ug/ml 8  {fraction(1/128)} 15.13 ug/ml 9  {fraction (1/256)} 7.56 ug/ml 10  {fraction(1/512)} 3.78 ug/ml 11   {fraction (1/1024)} 1.89 ug/ml 12 GC No extract13 NC No organism

[0136] Inoculation

[0137] The inoculation procedure was performed as follows:

[0138] 1. 100 ul of organism suspension was added to all of the tubesexcept Tube NC (non-inoculated control).

[0139] 2. 100 ul of additional media was added to NC.

[0140] 3. All tubes were incubated at the appropriate temperatures andintervals:

[0141] Fungi: 25° C. for 5-7 days

[0142] Bacteria: 37° C. for 24-48 hours

[0143] Recording Results by Observing Turbidity

[0144] Turbidity was closely examined and the following was determined:

[0145] 1. The presence of turbidity indicated growth; the absence ofturbidity indicated inhibition of growth.

[0146] 2. For any extract, a result was valid only if there wasturbidity (i.e. growth) in the Tube GC, and no turbidity in the Tube NC(i.e. no growth).

[0147] 3. The MIC was determined as the last tube in the series (i.e.the most diluted tube) with no turbidity. Mean Inhibitory Conclusions(g/ml) EtOH MeOH EtAc C. albicans 1000  250-1000 >2000 A. niger1000-2000 1000-2000 >2000 T. mentagr. ≦7.56 ≦7.56  250-1000 S. aureus31.25-62.50 31.25-62.50 1000-2000 E. coli 250 62.50-250   >2000

[0148] Results of the Experiment

[0149] From the foregoing experiment, the following results wereachieved:

[0150] 1. Results indicated that the ethanol and methanol Morindacitrifolia extracts had meaningful activity against all of themicroorganisms tested.

[0151] 2. Preliminary drying studies indicated that the activity usingthe ethanol and methanol extracts was in the 5-10 mg/ml range.

[0152] 3. Ethyl acetate extracts contained <10% of the amount found inthe ethanol and methanol extracts.

[0153] In conclusion, this study clearly established antifungal activityof specific Morinda citrifolia fruit juice extracts. The extractscontain hundreds of compounds, and at 1000 l/ml, there may be 100compounds at concentrations of 10 l/ml each. Thus, since the extractstested were not purified antimicrobial compounds, even very high MIC'smay be meaningful.

[0154] The present invention may be embodied in other specific formswithout departing from its spirit of essential characteristics. Thedescribed embodiments are to be considered in all respects only alillustrative and not restrictive. The scope of the invention is,therefore, indicated by the appended claims, rather than by theforegoing description. All changes that come within the meaning andrange of equivalency of the claims are to be embraced within their scope

What is claimed and desired to be secured by Letters Patent is:
 1. Amethod for treating Candidiasis, said method comprising the steps of:introducing a naturaceutical composition comprising a processed Morindacitrifolia product to an area or region of the body of a mammalinflicted with Candida albicans, said processed Morinda citrifoliaproduct comprising the active ingredient Quercetin.
 2. The method ofclaim 1, wherein said Quercetin is present in an amount between about0.1 and 20 percent by weight.
 3. The method of claim 1, wherein saidprocessed Morinda citrifolia product is present in an amount betweenabout 0.01 and 100 percent by weight.
 4. The method of claim 1, whereinsaid processed Morinda citrifolia product is processed Morindacitrifolia fruit juice.
 5. The method of claim 1, wherein said processedMorinda citrifolia product is a processed Morinda citrifolia extractselected from the group consisting of ethyl acetate, ethanol, methanol,and aqueous extracts.
 6. The method of claim 1, wherein said processedMorinda citrifolia product is processed Morinda citrifolia fruit juiceconcentrate.
 7. The method of claim 1, wherein said processed Morindacitrifolia product is processed Morinda citrifolia puree juice.
 8. Themethod of claim 1, wherein said processed Morinda citrifolia product isMorinda citrifolia oil extract.
 9. The method of claim 1, wherein saidprocessed Morinda citrifolia product is Morinda citrifolia dietaryfiber.
 10. The method of claim 1, wherein said processed Morindacitrifolia product further comprises Rutin as an additional activeingredient that synergistically works with said Quercetin to treat saidCandidiasis.
 11. The method of claim 10, wherein said Rutin is presentin an amount between about 0.1 and 20 percent by weight.
 12. The methodof claim 1, wherein said naturaceutical composition is embodied in anoral composition that is administered orally.
 13. The method of claim 1,wherein said naturaceutical composition is embodied in a topical dermalcomposition and is administered topically to said infected area andinternalized transdermally.
 14. The method of claim 1, wherein saidnaturaceutical composition is administered by injection into saidinfected area.
 15. The method of claim 1, wherein said naturaceuticalcomposition is administered intravenously.
 16. The method of claim 1,wherein said naturaceutical composition functions to inhibit theovergrowth of Bacillus cereus, Bacillus mycoids, Sarcina lutea, Candidaalbicans, Saccharomyces cerevisiae, Fusarium oxysporum var. vasinfectum,Macrophomina phaseoli, Diplodia oryzae, Rhizoctonia solani,Helminthosporium turcicum, Aspergillus carneus, and others to treat saidCandidiasis.
 17. The method of claim 1, wherein said processed Morindacitrifolia product comprises processed Morinda citrifolia fruit juiceconcentrate.
 18. The method of claim 1, wherein said processed Morindacitrifolia product comprises processed Morinda citrifolia puree juiceconcentrate.
 19. A method for inducing antimicrobial activity within thebody of a mammal to inhibit, prevent, and destroy Candida fungus and theovergrowth of Candida albicans, said method comprising the steps of:adding a processed Morinda citrifolia product to an alcohol-basedsolution; isolating and extracting an active ingredient of saidprocessed Morinda citrifolia product from said solution andincorporating said active ingredient in a naturaceutical formulation;and introducing a safe, pre-determined amount of said naturaceuticalformulation having a safe, pre-determined concentration of saidextracted active ingredient to an area infected with said Candida fungusintermittently for a safe, pre-identified amount of time.
 20. The methodof claim 19, wherein said processed Morinda citrifolia product comprisesprocessed Morinda citrifolia fruit juice.
 21. The method of claim 19,wherein said processed Morinda citrifolia food product comprisesprocessed Morinda citrifolia puree juice.
 22. The method of claim 19,wherein said alcohol-based solution is selected from the groupconsisting essentially of methanol, ethanol, and ethyl acetate, andother alcohol-based solutions.
 23. The method of claim 19, wherein saidactive ingredient is Quercetin.
 24. The method of claim 23, wherein saidactive ingredient is Rutin that synergistically works with saidQuercetin to induce antimicrobial activity, thus inhibiting andpreventing the overgrowth of said Candida albicans in said infectedarea.
 25. The method of claim 19, wherein said step of introducing saidextracted active ingredient to an area infected by said Candida albicanscomprises orally administering two ounces of said naturaceuticalformulation to a patient twice daily each day on an empty stomach, saidnaturaceutical formulation comprising said active ingredient as obtainedfrom said processed Morinda citrifolia product.
 26. The method of claim19, wherein said step of introducing said extracted active ingredient toan area infected by said Candida albicans comprises applying saidnaturaceutical formulation topically to said area, said naturaceuticalformulation embodied in a topical dermal naturaceutical compositioncomprising said active ingredient as obtained from said processedMorinda citrifolia product.
 27. A method for inhibiting, preventing, anddestroying the growth of candida albicans, said method comprising thesteps of: orally administering at least one ounce of a naturaceuticalformulation comprising a processed Morinda citrifolia product on anempty stomach in the morning; and orally administering at least oneounce of said naturaceutical formulation on an empty stomach prior tosleeping at night.
 28. The method of claim 27, wherein saidnaturaceutical formulation comprises: processed Morinda citrifolia fruitjuice present in an amount by weight of about 100 percent.
 29. Themethod of claim 27, wherein said naturaceutical formulation comprises:processed Morinda citrifolia fruit juice present in an amount by weightbetween about 10-99.99 percent; and water present in an amount by weightbetween about 0.1-90 percent.
 30. The method of claim 27, wherein saidnaturaceutical formulation comprises: processed Morinda citrifolia fruitjuice present in an amount by weight between about 10-99.9 percent; andother fruit juices present in an amount by weight between about 0.1-90percent.
 31. The method of claim 27, wherein said naturaceuticalformulation comprises: processed Morinda citrifolia fruit juice presentin an amount by weight between about 50-90 percent; water present in anamount by weight between about 0.1-50 percent; and other fruit juicespresent in an amount between about 0.1-30 percent.
 32. The method ofclaim 27, wherein said overgrowth of said Candida albicans is exhibitedby vaginal itching, vaginal burning, vaginal redness, vaginalinflammation and vaginal irritation.
 33. The method of claim 27, whereinsaid naturaceutical formulation is consumed by orally administering 2ounces of said naturaceutical formulation twice daily.
 34. A method fortreating Candidiasis comprising the steps of: orally administering atleast one ounce of a naturaceutical formulation on an empty stomach inthe morning, said naturaceutical formulation comprising at least oneprocessed Morinda citrifolia product; orally administering at least oneounce of said naturaceutical formulation prior to sleeping at night; andrepeating said steps of orally administering daily until growth of saidCandidiasis is abated.
 35. The method of claim 34, wherein saidnaturaceutical formulation comprises processed Morinda citrifolia pureejuice present in an amount by weight of about 100 percent.
 36. Themethod of claim 34, wherein said naturaceutical formulation comprises:processed Morinda citrifolia puree juice present in an amount by weightbetween about 85-99.99 percent; and water present in an amount by weightbetween about 0.1-15 percent.
 37. The method of claim 34, wherein saidnaturaceutical formulation comprises: processed Morinda citrifolia pureejuice present in an amount by weight between about 85-99.99 percent; andother fruit juices present in an amount by weight between about 0.1-15percent.
 38. The method of claim 34, wherein said naturaceuticalformulation comprises: processed Morinda citrifolia puree juice presentin an amount by weight between about 50-90 percent; water present in anamount by weight between about 0.1-50 percent; and other fruit juicespresent in an amount between about 0.1-30 percent.
 39. The method ofclaim 34, wherein said naturaceutical formulation is consumed by orallyadministering 2 ounces of said food product, twice daily.
 40. The methodof claim 34, wherein said naturaceutical formulation comprises processedMorinda citrifolia fruit juice present in an amount by weight of about100 percent.
 41. The method of claim 34, wherein said naturaceuticalformulation comprises: processed Morinda citrifolia fruit juice presentin an amount by weight between about 85-99.99 percent; and water presentin an amount by weight between about 0.1-15 percent.
 42. The method ofclaim 34, wherein said naturaceutical formulation comprises: processedMorinda citrifolia fruit juice present in an amount by weight betweenabout 85-99.99 percent; and other fruit juices present in an amount byweight between about 0.1-15 percent.
 43. The method of claim 34, whereinsaid naturaceutical formulation comprises: processed Morinda citrifoliafruit juice present in an amount by weight between about 50-90 percent;water present in an amount by weight between about 0.1-50 percent; andother fruit juices present in an amount between about 0.1-30 percent.44. A method for treating Candidiasis, said method comprising the stepof: topically introducing a portion of a naturaceutical formulation toan area infected with said Candidiasis intermittently each day untilgrowth is abated, said naturaceutical formulation comprising at leastone processed Morinda citrifolia product;.
 45. A method for relievingvaginal discomfort, including itching and swelling, caused by Candidaalbicans, said method comprising the steps of: orally administering atleast one ounce of a naturaceutical formulation comprising at least oneprocessed Morinda citrifolia product on an empty stomach in the morning;orally administering at least one ounce of said naturaceuticalformulation prior to sleeping at night; and repeating said steps oforally administering daily until growth is abated.
 46. The method ofclaim 45, wherein said vaginal discomfort includes vaginal itching,vaginal burning, vaginal redness, vaginal inflammation and vaginalirritation.
 47. The method of claim 45, wherein said vaginal discomfortis experienced during pregnancy.
 48. The method of claim 45, whereinsaid vaginal discomfort is experienced by a person taking prescriptionmedications.
 49. A method for inhibiting, preventing, and destroying thegrowth of Candida albicans, said method comprising the steps of:applying a topical naturaceutical formulation to an area infected withsaid Candida albicans, said topical naturaceutical formulationcomprising the ingredients of: a processed Morinda citrifolia productpresent in an amount by weight between about 10-80 percent; and acarrier composition present in an amount by weight between about 20-90percent.
 50. The method of claim 49, wherein said processed Morindacitrifolia product comprises processed Morinda citrifolia fruit juice.51. The method of claim 49, wherein said processed Morinda citrifoliaproduct comprises processed Morinda citrifolia puree juice.
 52. Themethod of claim 49, wherein said processed Morinda citrifolia productcomprises processed Morinda citrifolia dietary fiber.
 53. The method ofclaim 49, wherein said processed Morinda citrifolia product comprisesprocessed Morinda citrifolia oil extract.
 54. A method for inhibiting,preventing, and destroying the growth of Candida albicans, said methodcomprising the steps of: applying a topical naturaceutical formulationto an area infected with said Candida albicans, said topicalnaturaceutical formulation comprising the ingredients of: processedMorinda citrifolia oil present in an amount by weight between about0.1-20 percent; and a carrier composition present in an amount by weightbetween about 20-99.99 percent.
 55. A method for inhibiting, preventing,and destroying the growth of Candida albicans, said method comprisingthe steps of: applying a topical naturaceutical formulation to an areainfected with said Candida albicans, said topical naturaceuticalformulation comprising the ingredients of: processed Morinda citrifoliafruit juice present in an amount by weight between about 0.1-80 percent;processed Morinda citrifolia oil present in an amount by weight betweenabout 0.1-20 percent; and a carrier composition present in an amount byweight between about 20-90 percent.
 56. A method for inducingantimicrobial effects within the body, said method comprising the stepsof: introducing a naturaceutical composition comprising a processedMorinda citrifolia product to an area or region of the body of a mammalinflicted with Candida albicans, said processed Morinda citrifoliaproduct comprising an active ingredient.
 57. The method of claim 56,wherein said active ingredient is Rutin.
 58. The method of claim 56,wherein said active ingredient is Xeronine.
 59. The method of claim 56,wherein said active ingredient is Quercetin.
 60. A method for inhibitingand preventing the growth of Candida albicans within an infected regionof a mammal, said method comprising the steps of: introducing aninternal composition to said infected region, said internal compositioncomprising: a processed Morinda citrifolia product present in an amountby weight between about 0.1-90 percent; and a carrier medium present inan amount by weight between about 10-99.9 percent.
 61. The method ofclaim 60, wherein said processed Morinda citrifolia product is selectedfrom the group consisting of processed Morinda citrifolia fruit juice,processed Morinda citrifolia puree juice, processed Morinda citrifoliadietary fiber, processed Morinda citrifolia oil, processed Morindacitrifolia alcohol extracts, and processed Morinda citrifolia oilextract.
 62. The method of claim 60, wherein said step of introducing aninternal composition is done intravenously.
 63. The method of claim 60,wherein said step of introducing an internal composition is donetransdermally.
 64. The method of claim 60, wherein said step ofintroducing an internal composition is done systemically.
 65. A methodfor inducing antimicrobial activity and inhibiting and preventingovergrowth of Candida albicans within the body of a mammal for thepurpose of treating Candidiasis, said method comprising the steps of:administering a pharmaceutical medication formulated for treatment ofCandidiasis to a patient; administering a naturaceutical formulation tosaid patient concurrently with said pharmaceutical medication, saidnaturaceutical comprising at least one processed Morinda citrifoliaproduct that reduces and inhibits the breaking down and metabolizing ofsaid pharmaceutical medication by inhibiting the medication breakdownfunctions of said cytochrome enzymes, thus increasing the efficacy ofsaid pharmaceutical medication, said processed Morinda citrifoliaproduct present in an amount by weight between 0.1 and 100 percent. 66.A naturaceutical formulation for treating Candidiasis in mammalscomprising: at least one processed Morinda citrifolia product;
 67. Thenaturaceutical formulation of claim 66, wherein said processed Morindacitrifolia product comprises Morinda citrifolia fruit juice.
 68. Thenaturaceutical formulation of claim 66, wherein said processed Morindacitrifolia product comprises Morinda citrifolia puree juice.
 69. Thenaturaceutical formulation of claim 66, wherein said processed Morindacitrifolia product comprises Morinda citrifolia puree juice concentrate.70. The naturaceutical formulation of claim 66, wherein said processedMorinda citrifolia product comprises Morinda citrifolia fruit juiceconcentrate.
 71. The naturaceutical formulation of claim 66, whereinsaid processed Morinda citrifolia product comprises Morinda citrifoliadietary fiber.
 72. The naturaceutical formulation of claim 66, whereinsaid processed Morinda citrifolia product of said naturaceuticalformulation further comprises an active ingredient Quercetin present inan amount between about 0.1 and 10 percent by weight.
 73. Thenaturaceutical formulation of claim 66, wherein said processed Morindacitrifolia product is present in an amount between about 0.01 and 100percent by weight.
 74. The naturaceutical formulation of claim 72,wherein said processed Morinda citrifolia product further comprisesRutin as an additional active ingredient that synergistically works withsaid Quercetin to treat said Candidiasis and its associated symptoms.75. The naturaceutical formulation of claim 73, wherein said Rutin ispresent in an amount between about 0.1 and 10 percent by weight.
 76. Thenaturaceutical formulation of claim 66, wherein said naturaceutical isadministered orally.
 77. The naturaceutical formulation of claim 66,wherein said naturaceutical is administered transdermally to saidinfected area.
 78. The naturaceutical formulation of claim 66, whereinsaid naturaceutical is administered intravenously.
 79. Thenaturaceutical formulation of claim 66, wherein said naturaceutical isadministered systemically.